Financial Data and Key Metrics Changes - The company reported revenue of €926 million for H1 2025, reflecting a 6% increase on an underlying basis and a 5% increase on a reported basis [30][32] - Adjusted operating profit (AOP) reached €241 million, with a 10% increase on an underlying basis and a 7% increase on a reported basis [30][34] - Free cash flow improved significantly by 51%, totaling over €200 million [6][35] - Adjusted earnings per share (EPS) increased to €0.83 from €0.57 in H1 2024, marking a 46% year-on-year increase [31][39] Business Segment Data and Key Metrics Changes - The research segment generated underlying revenue of €727 million, with a 7% revenue growth and 8% AOP growth [9][30] - The health segment reported underlying revenue of €90 million, representing a 4% growth, with AOP increasing by 19% to €15 million [12][13] - The education segment saw underlying revenue of €108 million, reflecting a 3% growth, with a strong 6.5% growth in Q2 driven by curriculum business performance [14][30] Market Data and Key Metrics Changes - The global article market grew by about 6%, while the company's article output increased by about 10%, indicating market share gains [9][10] - The full open access market experienced 9% growth, with the company outperforming at 25% growth in this segment [10][30] Company Strategy and Development Direction - The company raised its guidance for the 2025 fiscal year, reflecting positive momentum across the business, particularly in research [7][39] - Investments in AI and technology are central to the company's strategy, with a focus on enhancing the research process and improving operational efficiency [6][16] - The company aims to maintain its leadership in open access publishing, having published over 50% of primary research content open access in H1 2025 [15][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business, supported by a high share of contracted revenues and a diversified global revenue base [41][60] - The company anticipates continued growth in the research segment, with strong submission volumes and publication growth expected to drive revenue [7][39] - Management noted that the impact of AI is viewed positively, as it is expected to enhance the publication process rather than disrupt it [70][72] Other Important Information - The company has launched several AI tools to improve the research workflow, including the Nature Research Assistant, which is currently in a controlled beta phase [24][25] - The company received a gold rating from EcoVadis for sustainability, placing it in the top 5% of companies assessed [20] Q&A Session Summary Question: Market share gains in full open access - Management attributed market share gains to the quality of their portfolio, increased journal launches, and investments in research integrity and AI [46][50] Question: Margin expansion targets - Management indicated that while they aim for 100 basis points of margin expansion, current performance may limit future expectations [47][53] Question: U.S. market environment for renewals - Management expressed optimism about the U.S. renewal campaign, noting that library budgets are resilient despite fluctuations in government funding [56][60] Question: Relationship with Digital Science - Management clarified that Digital Science is treated as an independent supplier, with no special relationship affecting their operations [62] Question: Potential disruption from AI - Management believes AI will enhance their business rather than disrupt it, as they focus on responsible AI use to improve the publication process [70][72] Question: Revenue guidance changes - Management explained that the revenue guidance upgrade is due to market share gains and improved visibility from completed renewals [67][72] Question: Future demand for open access journals - Management remains confident in their ability to capture market share despite potential competition from other open access publishers [87][89] Question: Share buyback considerations - Management stated that share buybacks would be considered once leverage is within the target range and free float increases [90][91] Question: Balance sheet capacity and acquisitions - Management emphasized a focus on deleveraging and interest expense reduction, with potential acquisitions being evaluated based on strategic fit [98][99]

Tencent (00700) Q2 2025 Earnings Call August 13, 2025 08:00 AM ET Company ParticipantsWendy Huang - IROPony Ma - Chairman & CEOMartin Lau - PresidentJames Mitchell - Chief Strategy Officer & Senior EVPJohn Lo - SVP & CFOThomas Chong - Managing DirectorAlex Yao - Co-Head of Asia Technology, Media & TelecommunicationsKenneth Fong - Managing DirectorRonald Keung - Managing DirectorCharlene Liu - Managing Director - Head of Internet & Gaming, Asia - PacificYuan Liao - Internet Media Research AssistantWilliam Pa ...

Financial Data and Key Metrics Changes - The company reported a GMV of $1,450,000,000, representing a 34% year-over-year increase, and revenues of almost $215,000,000, up 28% year-over-year [10][23] - Adjusted gross profit for Q2 was just shy of $100,000,000, up 24% from last year, with adjusted EBITDA of $38,500,000, up 23% compared to the same quarter last year, resulting in a 17.9% margin [10][26] - The company achieved GAAP profitability with a net profit of $10,500,000 compared to a net loss of $22,400,000 in the same quarter of last year [10][27] Business Line Data and Key Metrics Changes - Service fee revenue for the quarter was $102,900,000, while fulfillment services revenue was $112,000,000 [23] - The service fee take rate increased compared to Q1 2025, while the fulfillment take rate decreased as expected due to seasonal higher average order value [24] Market Data and Key Metrics Changes - The company continues to see strong growth across many geographies and cohorts of merchants, with notable expansions in the U.S. market [12][78] - The U.S. business has outperformed, driven by strong growth from digitally native brands [78] Company Strategy and Development Direction - The company extended its partnership with DHL for an additional three years, enhancing service offerings for merchants [14] - The acquisition of ReturnGo aims to improve post-purchase solutions for merchants, integrating advanced technology for returns and exchanges [15][49] - The company is focused on enhancing its 3B2C offering to help brands offset costs due to rising tariffs [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business model despite uncertainties around duty tariffs and trade dynamics [9][11] - The company anticipates continued strong trading patterns and does not expect significant impacts from upcoming changes to the U.S. de minimis exemption [11][36] Other Important Information - The company ended the quarter with $516,000,000 in cash and cash equivalents, with free cash flow of $63,500,000 [27] - For Q3 2025, the company expects GMV in the range of $1,455,000,000 to $1,495,000,000, representing a growth rate of 30% versus 2024 [28] Q&A Session Summary Question: Expectations around the de minimis exemption and its impact - Management indicated that they do not expect a significant impact from the removal of the de minimis exemption, noting resilient trading patterns [33][36] Question: Impact of the ReturnGo acquisition on revenue and OpEx - The acquisition is expected to have a slight positive impact on revenue and a minor negative impact on adjusted EBITDA in 2025, with expectations of neutral impact by 2026 [38] Question: Take rate dynamics for the 3B2C product - The take rate for the 3B2C solution is expected to be similar to regular B2C transactions, with minimal impact from clearance fees [45] Question: Growth in the U.S. business and its drivers - The U.S. business is outperforming due to strong growth from digitally native brands, contributing positively to overall performance [78] Question: Contribution from borderfree.com - The borderfree.com platform contributed over 4% of sales from merchants utilizing the service, in line with expectations [87] Question: Trends in NDR and same-store merchant GMV growth - Year-to-date figures are in line with historical averages, with expectations for new merchant contributions to be similar to last year [89]

Financial Data and Key Metrics Changes - The company ended the second quarter of 2025 with $77 million in cash and cash equivalents, with a net cash used in operating activities of $22.6 million, which included $2.4 million in severance payments [14] - Collaboration revenue for 2025 was $3.1 million, an increase from $2.3 million in the same period in 2024, primarily due to increased revenue from collaborations with J&J and Merck KGAA [15] - Research and development expenses for 2025 were $16.2 million, down from $17.2 million in 2024, attributed to lower headcount and related compensation costs [16] - General and administrative expenses decreased to $7.4 million from $10.5 million in 2024, mainly due to lower headcount and reduced consulting fees [17] - The net loss for the second quarter of both 2025 and 2024 was $24.3 million [18] Business Line Data and Key Metrics Changes - The company reported strong enrollment progress in the EMILY phase one trial, particularly in expansion cohorts targeting triple negative breast cancer (TNBC) [4][10] - Among evaluable patients with high B7-H4 tumor expression, the confirmed objective response rate (ORR) was 31% [5] - In patients with adenoid cystic carcinoma type one (ACC1), the ORR was 56% [6] Market Data and Key Metrics Changes - The market for topo one ADCs in TNBC is expected to grow significantly, with Trodelvy projected to generate about $1 billion in global revenues in 2025 [11] - The company believes the post-topo one TNBC opportunity is sizable and could expand as more agents move into earlier lines of therapy [11] Company Strategy and Development Direction - The company is focusing on addressing unmet needs in TNBC, particularly for patients previously treated with topo one ADCs [6][12] - The company is exploring the potential of EMILY as a second-line therapy for patients who have received prior topo one ADCs [12] - The company is also developing XMT-2056, an Immunosynthen ADC targeting HER2, with GSK holding an exclusive global license option [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for EMILY to meet significant unmet needs in the TNBC market [10][12] - The management highlighted the importance of the evolving treatment landscape and the potential for EMILY to address the needs of topo-experienced patients if approved [11] Other Important Information - The company incurred $3.9 million in restructuring charges primarily related to severance and benefit payments [17] - The company expects its capital resources to support its operating plan commitments into mid-2026 [14] Q&A Session Summary Question: Expectations for upcoming data in the second half - Management indicated that the data will be based on over 45 enrolled patients, with both dose A and B included, but cautioned about committing to an exact number due to treatment and scan requirements [21][22] Question: Good benchmark for efficacy - Management stated that a response rate in the 20s and a median PFS of 16 weeks would be a good benchmark, considering the standard of care has a 5% response rate and 6-7 weeks PFS [23] Question: Implementation of proteinuria mitigation strategies - Management confirmed that Amendment five was implemented to minimize proteinuria development, allowing patients to continue treatment despite isolated albuminuria [28] Question: Enrollment progress and potential next steps - Management reported that enrollment is going well, with no need for additional sites for the expansion, and they are focused on TNBC for the pivotal study [50][67] Question: Milestone payment details - The $15 million milestone payment is development-based, but further details remain confidential [58]

BiomX (PHGE) Q2 2025 Earnings Call August 13, 2025 08:00 AM ET Speaker0Good morning and welcome to the BioMix Second Quarter twenty twenty five Financial Results and Business and Program Update Conference Call. Currently, all participants are in a listen only mode. At the end of this call, there will be a question and answer session. As a reminder, this conference call is being recorded. I would now like to turn the call over to Marina Wolfson, Chief Financial Officer of BioMix.Please proceed.Speaker1Thank ...

Financial Data and Key Metrics Changes - Total revenue for the second quarter was RMB185 billion, representing a 15% year-on-year increase [7] - Gross profit reached RMB105 billion, up 22% year-on-year [7] - Non-IFRS operating profit was RMB69 billion, an 18% increase year-on-year [7] - Non-IFRS net profit attributable to equity holders was RMB63 billion, up 10% year-on-year [7] - Excluding associated profit contributions, underlying net profit would have increased by 20% year-on-year [7][30] - Overall gross margin improved to 57%, up four percentage points year-on-year [31] Business Line Data and Key Metrics Changes - Value-added services (VAS) revenue was RMB91 billion, up 16% year-on-year [12] - Social networks revenue increased by 6% year-on-year, driven by app-based game item sales and music subscriptions [13] - Domestic games revenue grew by 17% year-on-year, supported by titles like Delta Force and Honor of Kings [14] - International games revenue surged by 35% year-on-year, driven by Supercell's games and PUBG Mobile [15] - Marketing services revenue grew 20% year-on-year to RMB36 billion, benefiting from AI-powered ad tech upgrades [23] - FinTech and business services revenue was RMB56 billion, up 10% year-on-year [24] Market Data and Key Metrics Changes - Combined monthly active users (MAU) of Weixin and WeChat reached 1.4 billion, showing growth year-on-year and quarter-on-quarter [8] - GMV facilitated by Mini Programs grew by a teens percentage year-on-year [15] - Mini games' total gross receipts increased by 20% year-on-year [15] - Weixin search revenue grew around 60% year-on-year due to enhanced ad relevance [24] Company Strategy and Development Direction - The company is focusing on integrating AI across its platforms to enhance user experience and drive revenue growth [5][6] - There is a strong emphasis on developing evergreen games and expanding the gaming portfolio to reduce volatility [18][82] - The company aims to leverage AI capabilities to improve advertising performance and user engagement [23][39] - The strategy includes enhancing the functionalities of AI-native applications like Yanbao and improving the overall ecosystem [17][47] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of advertising revenue, driven by AI enhancements [39] - The company noted that the gaming market in China is evolving, with increasing demand for both live service and AAA games [58][96] - Management highlighted the importance of maintaining a balance between AI investment and cost management [61][104] - The company anticipates sustained growth in commercial payment volume, driven by improved transaction dynamics [91] Other Important Information - The company reported a significant increase in operating CapEx, reaching RMB19.1 billion, up 119% year-on-year, primarily due to investments in AI capabilities [33] - Free cash flow was RMB43 billion, up 7% year-on-year, driven by growth in games gross receipts [34] - The net cash position was RMB74.6 billion, down 17% quarter-on-quarter due to dividend payments [34] Q&A Session Summary Question: Potential of marketing services and advertising growth - Management believes there is a long runway for advertising revenue growth, driven by improved click-through rates and traffic [38][39] Question: Consumer behavior changes with AI features - Management noted that AI features enhance user satisfaction and efficiency, with minimal negative impact on traditional content consumption [45][46] Question: Impact of new advertising law on gaming companies - Management does not expect a meaningful impact from the new advertising regulations, citing broad-based growth in advertising revenue [70] Question: Business services revenue growth and GPU allocation - Management indicated that business services revenue growth is broad-based and not solely dependent on GPU availability [76] Question: AAA gaming growth in China - Management sees potential for AAA games in China but believes live service games will remain the majority of the market [58][96]

Financial Data and Key Metrics Changes - The company reported underlying revenue growth of 6% and adjusted operating profit (AOP) increasing by 10% in H1 2025 [5][34] - Free cash flow increased by 51%, totaling more than €200 million in 2025 [6] - Adjusted earnings per share rose to €0.83 from €0.57 in H1 2024 [43] Business Segment Data and Key Metrics Changes - The research segment generated underlying revenue of €727 million, with 7% revenue growth and 8% AOP growth [9] - Health segment reported underlying revenue of €90 million, representing 4% growth, with AOP increasing by 19% to €15 million [13] - Education segment reported underlying revenue of €108 million, with a growth of about 3% [14] Market Data and Key Metrics Changes - The global article market grew by about 6%, while the company's article output increased by about 10% [10] - The full open access market saw 9% growth, with the company outperforming at 25% growth [11] Company Strategy and Development Direction - The company has raised its guidance for the 2025 fiscal year, reflecting positive momentum, particularly in research [7][43] - Investments in AI and technology are aimed at transforming the research ecosystem, with over 90 AI applications in use [17][24] - The company continues to focus on open access as a core pillar of its research strategy, publishing over 50% of primary research content open access [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business, supported by a high share of contracted revenues [45] - The company expects underlying group revenue to be between €1.96 billion and €1.98 billion for 2025, assuming stable economic conditions [44] Other Important Information - The company launched 24 new journals in the first half of the year, including Nature Clean Technology and Nature Biodiversity [11] - The company received a gold rating from EcoVadis for sustainability, placing it in the top 5% of companies [22] Q&A Session Summary Question: What attributed to the 25% growth in full open access published articles? - Management attributed the growth to the quality of the portfolio, increased investment in new journals, and enhanced research integrity initiatives [49][52] Question: Will margin expansion targets change due to current performance? - Management indicated that while current performance is strong, they would focus on 2025 before discussing midterm margin expansion targets [50][56] Question: How is the market environment in the U.S. for the 2026 renewal campaign? - Management noted that the U.S. market remains resilient, with a significant portion of revenues contracted, and they expect a smaller number of renewals in 2026 [60][63] Question: How does the company view potential disruption from AI? - Management believes that AI will positively impact the industry by improving the publication process and reducing friction, rather than being a disruptive force [70][75] Question: What factors drove the significant change in revenue guidance? - Management expects H2 growth to be in line with H1, driven by completed renewals and strong submission volumes [71][76] Question: What is the expected adjusted effective tax rate for the full year? - Management anticipates the tax rate to decrease to around 12% for the full year due to recent changes in German corporate tax legislation [81] Question: At what level of leverage would the company consider share buybacks? - Management stated that share buybacks would be considered once the free float increases and after achieving their deleveraging targets [88][92]

Financial Data and Key Metrics Changes - In Q2 2025, revenue increased by 19.3% year over year, reaching a record of $17,700,000, supported by demand for the Intelligent Service Assurance platform [6][10][24] - Operating income rose by more than 50% compared to Q2 last year, with non-GAAP operating margin expanding to nearly 20% of revenue [10][24] - Non-GAAP net income was $4,200,000, or $0.25 per diluted share, compared to $3,100,000, or $0.20 per diluted share last year [29] - The company ended Q2 with over $100,000,000 in cash, the highest in its history, and remains debt-free [10][29] Business Line Data and Key Metrics Changes - The company reported solid profitability and cash generation, with positive cash flow of $2,600,000 during the quarter [10][29] - Non-GAAP gross margin for Q2 2025 was 76.2%, reflecting effective expense management while investing in growth [24] Market Data and Key Metrics Changes - The telecom industry is experiencing transformation driven by the convergence of 5G and AI, with significant challenges for operators due to data volume growth and IoT adoption [17][18] - In Q1 alone, operators added 145,000,000 new 5G subscriptions globally, bringing the total to 2,400,000,000 [19] Company Strategy and Development Direction - The company is focused on becoming a key vendor in the intelligent, agentic AI-powered ecosystem, addressing operators' pain points and future market drivers [9][11] - Strategic partnerships, including collaboration with NVIDIA, are expected to drive incremental value and expand the addressable market [12][21] - The company aims to deliver advanced service assurance frameworks to support operators' AI-driven customer-centric vision [11][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year revenue growth guidance of 15% to 18%, supported by healthy customer engagement and market shifts towards intelligent, automated assurance [21][22] - The company is actively engaged in field trials with Tier 1 operators in key markets such as North America, Japan, and EMEA [13][19] Other Important Information - The company did not receive a grant from the Israel Innovation Authority this quarter, compared to $180,000 received in the same quarter last year, but anticipates securing grants in Q3 and Q4 [27] - Non-GAAP operating income for Q2 was $3,400,000, representing 19.5% of quarterly revenues, an increase of $1,200,000 from the previous year [28] Q&A Session Summary Question: How is the partnership with service management system vendors like ServiceNow and AWS going? - The partnership is progressing well, with co-development and interconnecting platforms already in place [34] Question: How should we think about the capital allocation with $100,000,000 in cash? - The company is considering potential M&A as a priority and is progressing with a few candidates [35] Question: What percentage of the pipeline is coming from existing customer expansion versus new logo wins? - Approximately two-thirds of growth is expected from existing customers and one-third from new customers [39] Question: What percentage of current revenue is coming from 5G versus legacy network revenue? - A significant portion of LTE networks is still operational, and while 5G is growing, it will take time for full transformation [40] Question: Any updates on the RFP process for new Tier 1 opportunities? - The company is participating in several RFPs globally and expects decisions on a few within the next half of the year [41] Question: Is there an opportunity in the direct-to-device satellite space? - There are active opportunities, but clarity on capital allocation from certain customers is still pending [43] Question: Any changes in the competitive environment relative to peers? - The competitive landscape remains stable, with competitors shifting focus while the company continues to invest in innovation [44]

Financial Data and Key Metrics Changes - Consolidated revenue for the first quarter was $1,100 million, a 2% increase compared to the same quarter last year [36] - Adjusted segment operating income rose to $147.8 million, up 10% from $134.2 million in the previous year [36] - Adjusted earnings per share (EPS) remained stable at $0.21, consistent with the first quarter last year [36] - Net finance expense increased to $54.6 million from $49.5 million, primarily due to additional lease financing costs [36] - Free cash flow was negative $36.2 million, compared to negative $25.3 million in the first quarter last year [38] - Net debt position at the end of the quarter was approximately $3.2 billion, with a net debt to adjusted EBITDA ratio of 2.75 times [39] Business Line Data and Key Metrics Changes - In the civil segment, revenue grew 3% year over year to $607.7 million, while adjusted operating income rose 1% to $107.6 million, resulting in a 17.7% margin [41] - The defense segment's revenue remained stable at $490.9 million, with adjusted segment operating income increasing 45% to $40.2 million, delivering an 8.2% margin [42] Market Data and Key Metrics Changes - The civil aviation market is expected to see a recovery in demand for commercial training solutions, with a positive inflection anticipated in the second half of the fiscal year [19][22] - The defense market is experiencing a generational upcycle driven by rising geopolitical tensions and increased spending across NATO, the EU, and Canada [17][18] Company Strategy and Development Direction - The company aims to enhance shareholder value through deleveraging the balance sheet, targeting a net debt to adjusted EBITDA ratio of approximately 2.5 times by fiscal year-end [7] - Focus on operational excellence, capital allocation, and improving free cash flow conversion to drive stronger returns on invested capital [6][47] - The company is positioning itself as a strategic partner in defense, engaging with government leaders and aligning with national priorities [9][48] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the next three to five years, citing strong market fundamentals and a clear path to delivering stronger returns [14][15] - The company anticipates a recovery in pilot hiring and training demand, with encouraging signs of stabilization in the commercial aviation sector [21][22] - The defense business is expected to provide a predictable revenue stream and balance the portfolio, complementing growth in civil aviation [18] Other Important Information - The company opened its first dedicated training center in Central Europe, reflecting its commitment to supporting customers closer to their operations [23] - The company has a buyback program in place and may consider reinstating dividends at the appropriate time [7] Q&A Session Summary Question: Opportunities for improving margins and cash flow conversion - Management acknowledged significant investments made in capabilities and sees potential for optimization in operational efficiency [52][56] Question: Impact of transient headwinds on near-term CapEx spending - Management confirmed that CapEx is expected to be slightly lower year over year, with a disciplined approach to capital deployment [63] Question: Indicators for a rebound in airline pilot training demand - Management noted that increased hiring activity is expected as airlines resume hiring, supported by improved aircraft deliveries [70][74] Question: Executive compensation alignment with operational efficiency goals - Management indicated that they are assessing various metrics for executive compensation, including return on capital and free cash flow [78][81] Question: Defense margin guidance and contract mix - Management expressed confidence in executing their strategy and maintaining margins, with a focus on replacing lower-margin contracts with more accretive ones [84][86] Question: CAE's positioning in the US defense market - Management highlighted the unique growth opportunities in the US defense market and CAE's potential to leverage its capabilities across its portfolio [90]

Financial Data and Key Metrics Changes - As of June 30, 2025, the company's cash, cash equivalents, and short-term investments were $30 million, down from $44.1 million as of December 31, 2024. However, including net proceeds from a July private placement, the pro forma cash position is approximately $60 million, which is expected to fund planned clinical studies and operations into 2027 [14][15][17] - The net loss for the three and six months ending June 30, 2025, was $7.7 million and $15.4 million, respectively, compared to $5.1 million and $10.3 million for the same periods in 2024, indicating an increase in net loss year-over-year [17] Business Line Data and Key Metrics Changes - Research and Development (R&D) expenses increased to $5.8 million and $11.5 million for the three and six months ended June 30, 2025, compared to $3.9 million and $7.6 million for the same periods in 2024, primarily due to costs associated with the REMEDY two clinical trial and expansion of the clinical team [15] - General and administrative expenses also rose to $2.2 million and $4.7 million for the three and six months ended June 30, 2025, compared to $1.7 million and $3.8 million in the prior year, driven by increased personnel costs and non-cash share-based compensation [16] Market Data and Key Metrics Changes - DiaMedica was added to the US small cap Russell 2000 and Russell 3000 indexes, enhancing visibility among institutional investors and the broader investment community [12] Company Strategy and Development Direction - The company is advancing its DM199 program for preeclampsia, with plans to conduct a Phase 2B trial in the US and other countries, and is preparing an FDA IND application [8][9] - The company aims to finalize a dosing regimen for the ongoing clinical trials and expand its indications to include fetal growth restriction [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the current cash position and its ability to fund clinical studies into 2027, despite an increase in net losses [14][17] - The interim results from the preeclampsia program were described as highly promising, with DM199 showing significant efficacy in managing maternal hypertension [6][9] Other Important Information - The company completed a $30 million private placement of common shares, which extends its cash runway into 2027 [9] - The new Chief Medical Officer, Dr. Julie Krop, brings extensive experience in the biopharma industry, particularly in women's health and preeclampsia [12][13] Q&A Session Summary Question: Why did Dr. Krop join the company, and what are her thoughts on the stroke program? - Dr. Krop expressed a strong commitment to women's health and excitement about the company's programs, highlighting the unmet needs in preeclampsia and ischemic stroke [20][21] Question: Can the company provide a timeline for the upcoming cohorts in the preeclampsia study? - Management indicated that Cohort 10 of Part 1B would start soon, with plans to push dosing higher and move into Part 2 and the fetal growth restriction cohort concurrently [25][27] Question: What is the current status of enrollment in the stroke study? - The company is currently at approximately 40 sites and is seeing an encouraging uptick in enrollment, with expectations for interim analysis to be completed in Q2 2026 [33][34] Question: Will the Phase 2B study have a primary endpoint that reflects pivotal regulatory endpoints for Phase 3? - Management stated that they are finalizing the protocol and are confident about the primary endpoint based on recent FDA feedback, but details will be shared once finalized [40]